Validation of 18F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: A stereotactic PET and MRI study

Clinical Nuclear Medicine

Volumn 38, Issue 7, 2013, Pages 495-500

  Mertens, Koen ^a   Acou, Marjan ^a   Van Hauwe, Jel ^a   De Ruyck, Ine ^a   Van Den Broecke, Caroline ^a   Kalala, Jean Pierre Okito ^a   D'Asseler, Yves ^a   Goethals, Ingeborg ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

18F FDG PET; Gliomas; Grading; Stereotactic biopsy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATIONAL STUDY; FEMALE; GLIOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; STEREOTACTIC BIOPSY; BRAIN TUMOR; CANCER GRADING; DIAGNOSTIC USE; MULTIMODAL IMAGING; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; STEREOTACTIC PROCEDURE; VALIDATION STUDY;

ADULT; BRAIN NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; STEREOTAXIC TECHNIQUES;

EID: 84880375375     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318292a753     Document Type: Article

References (33)

1. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329.
2. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816-822.
3. Di Chiro G, Hatazawa J, Katz DA, et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: A PET study. Radiology. 1987;164:521-526.
4. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 1988;62:1074-1078.
5. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from highgrade brain tumors with PET. Radiology. 1995;195:47-52.
6. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
7. De Witte O, Levivier M, Violon P, et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery. 1996;39:470-476; discussion 476-477.
8. Colavolpe C, Metellus P, Mancini J, et al. Independent prognostic value of pretreatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2012;107:527-535.
9. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer. 1989;64:442-447.
10. Francavilla TL, Miletich RS, Di Chiro G, et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery. 1989;24:1-5.
11. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-785.
12. Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomographyguided stereotactic biopsy. Cancer. 1996;78:1098-1106.
13. Ishizu K, Nishizawa S, Yonekura Y, et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med. 1994;35:1104-1109.
14. Ishizu K, Sadato N, Yonekura Y, et al. Enhanced detection of brain tumors by [18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr. 1994;18:12-15.
15. Spence AM, Muzi M, Mankoff DA, et al. 18F-FDG PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653-1659.
16. Pirotte B, Goldman S, Brucher JM, et al. PET in stereotactic conditions increases the diagnostic yield of brain biopsy. Stereotact Funct Neurosurg. 1994;63:144-149.
17. Pirotte B, Goldman S, Bidaut LM, et al. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien). 1995; 134:79-82.
18. Levivier M, Goldman S, Pirotte B, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F] fluorodeoxyglucose. J Neurosurg. 1995;82:445-452.
19. Dean BL, Drayer BP, Bird CR, et al. GliomasVclassification with MR imaging. Radiology. 1990;174:411-415.
20. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: Dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology. 2002;223:11-29.
21. Aronen HJ, Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am. 2002;12:501-523.
22. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am. 2009;19:527-557.
23. Hermann EJ, Hattingen E, Krauss JK, et al. Stereotactic biopsy in gliomas guided by 3-tesla (1)H-chemical-shift imaging of choline. Stereotact Funct Neurosurg. 2008;86:300-307.
24. Frati A, Pichierri A, Bastianello S, et al. Stereotactic cerebral biopsy: Our experience in 296 cases. Stereotact Funct Neurosurg. 2011;89:234-245.
25. Law M, Yang S, Wang H, et al. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR AM J Neuroradiol. 2003;24:1989-1998.
26. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo H-1 magnetic resonance spectroscopy. Magn Reson Med. 2003;49:223-232.
27. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas. J Neurosurg. 2007;106:660-666.
28. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007; 48:1468-1481.
29. Chen W, Silverman DH. Advances in evaluation of primary brain tumors. Semin Nucl Med. 2008;38:240-250.
30. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: A comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997;38:1459-1462.
31. Seo YS, Chung TW, Kim IY, et al. Enhanced detectability of recurrent brain tumor using glucose-loading F-18 FDG PET. Clin Nucl Med. 2008;33:32-33.
32. Farid K, Sibon I, Fernandez P, et al. Delayed acquisition and hyperglycemia improve brain metastasis detection on F-18 FDG PET. Clin Nucl Med. 2009;34:533-534.
33. Kim DW, Jung SA, Kim CG, et al. The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med. 2010;35:400-403.